EHA 2023 | PhALLCON: Phase III study of ponatinib vs imatinib in newly diagnosed Ph+ ALL
Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, briefly comments on the results of the PhALLCON trial (NCT03589326) comparing ponatinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Results showed ponatinib was superior to imatinib in combination with reduced-intensity chemotherapy, with a higher measurable residual disease (MRD)-negative complete response (CR) rate. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
